United States:
Select Issues In Negotiating Drug Pricing And Reimbursement Contracts
27 October 2016
BakerHostetler
To print this article, all you need is to be registered or login on Mondaq.com.
Lee H. Rosebush
and Lindsay P.
Holmes have authored a white paper on “Select Issues in
Negotiating Drug Pricing and Reimbursement Contracts” that is
published in the
October 2016 issue of HLA's Journal of Health & Life
Sciences Law.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...
